Document is current

Article History

Received: 30 April 2024

Revised: 30 May 2024

Accepted: 10 June 2024

First Online: 2 July 2024

Declarations

:

: Institutional Review Board number 202310190 was obtained for this retrospective analysis. Informed consent was not required for the study.

: The authors declare no competing interests.

: SSV, AS, DJO, ES, SS, AG: NoneEIL: Board Membership: Stryker, NeXtGen Biologics, MedX Health, Cog-nition Medical, EndoStream; Consultancy: Claret Medical, GLG Con-sulting, Guidepoint, Imperative Care, Medtronic, Rebound Therapeu-tics, StimMed; Employment: University at Buffalo Neurosurgery Inc;Expert Testimony: renders medical/legal opinions as an expert witness;Stock/Stock Options: NeXtGen Biologics, Cognition Medical, RapidMedical, Claret Medical, Imperative Care, Rebound Therapeutics,StimMedAHS: inancial interest/investor/stock options/ownership: Adona Medical, Inc., Amnis Therapeutics, BlinkTBI, Inc.,Boston Scientific Corp. (for purchase of Claret Medical), BuffaloTechnology Partners, Inc., Cardinal Consultants, LLC, CerebrotechMedical Systems, Inc., Cognition Medical, Endostream Medical,Ltd, Imperative Care, Inc., International Medical Distribution Part-ners, Neurovascular Diagnostics, Inc., Q’Apel Medical, Inc., RadicalCatheter Technologies, Inc., Rebound Therapeutics Corp. (purchased2019 by Integra Lifesciences, Corp.), Rist Neurovascular, Inc., SenseDiagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Spin-naker Medical, Inc., StimMed, Synchron, Three Rivers Medical, Inc.,Vastrax, LLC, VICIS, Inc., Viseon, Inc.; consultant/advisory board:Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA,Inc., Cerebrotech Medical Systems, Inc., Cerenovus, Corindus, Inc.,Endostream Medical, Ltd, Imperative Care, Inc., Integra LifeSciencesCorp., Medtronic, MicroVention, Minnetronix Neuro, Inc., North-west University—DSMB Chair for HEAT Trial, Penumbra, Q’ApelMedical, Inc., Rapid Medical, Rebound Therapeutics Corp., SerenityMedical, Inc., Silk Road Medical, StimMed, Stryker, Three RiversMedical, Inc., VasSol, W.L. Gore & Associates; national PI/steeringcommittees: Cerenovus LARGE trial and ARISE II trial, MedtronicSWIFT PRIME and SWIFT DIRECT trials, MicroVention FRED Trialand CONFIDENCE study, MUSC POSITIVE trial, Penumbra 3D Sep-arator trial, COMPASS trial, INVEST trial; research grants: co-inves-tigator, NIH/NINDS 1R01NS091075 Virtual Intervention of Intracra-nial Aneurysms; role: co-principal investigator, NIH-NINDS R21NS109575-01 Optimizing Approaches to Endovascular Therapy ofAcute Ischemic StrokeVMT: Financial interest/investor/stockoptions/ownership: Neurovascular Diagnostics, Inc., QAS.AI, Inc.;Consultant/advisory board: Canon Medical Systems USA; Researchgrants: Principal investigator, National Science Foundation Award No.1746694 and NIH NINDS award R43 NS115314-0; awardee of a Brain Aneurysm Foundation grant, a Center for Advanced Technology grant, and a Cummings Foundation grantEAS: Consultant for Medtronic, Microvention, Cerenovus, iSchemaView, and Rapid Medical